Transaction details and holdings
Rezolute, Inc. (NASDAQ: RZLT) reported that its Chief Financial Officer, Daron Evans, purchased 10,000 common shares on March 30, 2026, at a price of $2.85 per share. The total value of the transaction was $28,500. Following this direct purchase, Evans now owns 414,462 shares of Rezolute outright.
Evans' Form 4 filing with the Securities and Exchange Commission also lists indirect holdings through related parties and entities. The filing shows 23,000 shares held by minor child #1, 7,000 shares held by minor child #2, 7,000 shares held by minor child #3, 40,000 shares held by PoC Capital LLC, and 20,000 shares held by his spouse.
Share price context
The purchase occurred after the company’s stock fell approximately 70% over the prior six months. Year-to-date, shares have recovered about 21% and are trading at $3.05. An InvestingPro analysis referenced in company commentary indicates the stock appears slightly undervalued at current levels. Investors interested in further valuation detail are directed to comprehensive Pro Research Reports covering RZLT and more than 1,400 other U.S. equities.
Regulatory developments and analyst reactions
Separately, Rezolute has been in active dialogue with the U.S. Food and Drug Administration concerning ersodetug, its candidate for treating congenital hyperinsulinism. The company held a Type B meeting with the FDA, a development that prompted several analyst firms to update or reaffirm their coverage of the stock.
Following the regulatory interaction, Wedbush upgraded Rezolute’s rating to Outperform from Neutral and raised its price target to $5.00. H.C. Wainwright maintained a Buy rating with a $5.00 target, pointing to the FDA’s suggestion to submit comprehensive study reports for independent review. Cantor Fitzgerald reiterated a Neutral rating, noting the FDA is considering multiple approval pathways despite the drug not meeting its primary outcome in the Phase 3 sunRIZE study. Citizens kept a Market Perform rating after Rezolute outlined next steps for its program. BTIG also reiterated a Buy rating and left its $5.00 target intact, highlighting the FDA’s encouragement to submit additional data.
What this means for investors
The insider purchase increases the CFO’s direct stake and occurs against a backdrop of heavy recent volatility in the stock price and active regulatory engagement. Analyst reactions are mixed, with several firms endorsing further review and potential data submission to the FDA as the company seeks a path forward for ersodetug.
Readers seeking additional valuation tools or deeper research on RZLT can consult InvestingPro’s Fair Value calculator and Pro Research Reports for detailed model-driven insights.